INTERIM REPORT JANUARY - SEPTEMBER 2009

Launch of new probiotic juice with Skånemejerier

• Net sales for the interim period amounted to 49.7 million SEK (52.2) and to 14.3 million SEK (16.5) for the third quarter. • EBIT for the interim period amounted to 12.0 million SEK (7.8) and to 3.1 million SEK (2.9) for the third quarter, an increase of 55 percent for the interim period. • Profit after tax for the interim period amounted to 9.3 million SEK (6.6) and to 2.1 million SEK (2.5) for the third quarter. • Earnings per share for the interim period amounted to 1.00 SEK (0.71) and to 0.23 SEK (0.26) for the third quarter. • Cash flow for the interim period amounted to 11.6 million SEK (8.3) and to 2.5 milliong SEK (2.7) for the third quarter. • A new probiotic juice with positive effects on the immune system was launched during the third quarter together with Skånemejerier. • ProViva sales continues to develop positively. • Probi forecasts EBIT and cash flow to be positive during 2009. CEO’s COMMENTS: ”It is pleasing to, together with Skånemejerier, so quickly be able to turn our research into a new product such as Bravo Friscus. It is the world’s first probiotic juice with clinically proven effects on common cold symptoms and the immune system. In the long run we see the possibility for Bravo Friscus to develop in the same way as ProViva,” says Michael Oredsson, CEO of Probi.

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links